{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T15:40:26Z","timestamp":1767109226337},"reference-count":28,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"NeoRHEA","award":["NCT03065621"],"award-info":[{"award-number":["NCT03065621"]}]},{"name":"Institute: Roche, Menarini Silicon Biosystems, Janssen Diagnostics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1093\/annonc\/mdy456","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T19:24:13Z","timestamp":1539113053000},"page":"2274-2278","source":"Crossref","is-referenced-by-count":6,"title":["CDK4\/6 inhibitors as neoadjuvant treatment in breast cancer\u2014what can we learn?"],"prefix":"10.1016","volume":"29","author":[{"given":"M.","family":"Brand\u00e3o","sequence":"first","affiliation":[]},{"given":"M.","family":"Ignatiadis","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"5","key":"10.1093\/annonc\/mdy456_bb0010","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.breast.2014.06.004","article-title":"Current and future role of neoadjuvant therapy for breast cancer","volume":"23","author":"Untch","year":"2014","journal-title":"Breast"},{"issue":"20","key":"10.1093\/annonc\/mdy456_bb0015","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1093\/annonc\/mdy456_bb0020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1093\/annonc\/mdy456_bb0025","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-16-3206","article-title":"NeoPalAna: neoadjuvant Palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdy456_bb0030","article-title":"Abstract PD5-01: final results of NeoMONARCH: a phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC)","volume":"78","author":"Martin","year":"2018","journal-title":"Cancer Res"},{"issue":"2","key":"10.1093\/annonc\/mdy456_bb0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1530\/ERC-17-0396","article-title":"Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict\u2019s value","volume":"25","author":"Chow","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1093\/annonc\/mdy456_bb0040","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy448","article-title":"Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer","author":"Cottu","year":"2018","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdy456_bb0045","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","article-title":"Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis","volume":"2","author":"Spring","year":"2016","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdy456_bb0050","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1023\/A:1013128213451","article-title":"Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study","volume":"12","author":"Eiermann","year":"2001","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1093\/annonc\/mdy456_bb0055","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","article-title":"Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer","volume":"27","author":"Baselga","year":"2009","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1093\/annonc\/mdy456_bb0060","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"Ellis","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy456_bb0065","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10549-014-3183-4","article-title":"NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer","volume":"148","author":"Palmieri","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdy456_bb0070","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx440.001","article-title":"LBA10_PRPrimary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+\/HER2-negative early breast cancer (EBC)","author":"Saura","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy456_bb0075","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-011-1947-7","article-title":"Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study","volume":"133","author":"Kuter","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1093\/annonc\/mdy456_bb0080","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jnci\/djk020","article-title":"Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer","volume":"99","author":"Dowsett","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"10.1093\/annonc\/mdy456_bb0085","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/jnci\/djn309","article-title":"Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics","volume":"100","author":"Ellis","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"#cr-split#-10.1093\/annonc\/mdy456_bb0090.1","doi-asserted-by":"crossref","unstructured":"JFR Robertson, M Dowsett, JM Bliss et al. Abstract GS1-03: Peri-operative aromatase inhibitor treatment in determining or predicting longterm outcome in early breast cancer - The POETIC* Trial (CRUK\/07\/015). Cancer Res 2018","DOI":"10.1158\/1538-7445.SABCS17-GS1-03"},{"key":"#cr-split#-10.1093\/annonc\/mdy456_bb0090.2","unstructured":"doi: 10.1158\/1538-7445. http:\/\/cancerres.aacrjournals.org\/content\/78\/4_Supplement\/GS1-03 (26 October 2018, date last accessed)."},{"issue":"22","key":"10.1093\/annonc\/mdy456_bb0095","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1093\/annonc\/mdy456_bb0100","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrclinonc.2013.124","article-title":"Luminal breast cancer: from biology to treatment","volume":"10","author":"Ignatiadis","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdy456_bb0105","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdy456_bb0110","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw435.05","article-title":"Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER +\/HER2\u2013 advanced breast cancer (ABC)","author":"Finn","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy456_bb0115","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41467-018-03215-x","article-title":"Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer","volume":"9","author":"O'Leary","year":"2018","journal-title":"Nat Commun"},{"issue":"8","key":"10.1093\/annonc\/mdy456_bb0120","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdy456_bb0125","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-18-0264","article-title":"The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial","author":"O\u2019Leary","year":"2018","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1093\/annonc\/mdy456_bb0130","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.15252\/emmm.201607084","article-title":"CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib","volume":"9","author":"Rasp\u00e9","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"7668","key":"10.1093\/annonc\/mdy456_bb0135","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1093\/annonc\/mdy456_bb0140","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419342437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419342437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/12\/2274\/27342151\/mdy456.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:38:01Z","timestamp":1624696681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419342437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0923753419342437"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy456","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}